Articles

Research jobs could flow from Purdue quad

Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.

Read More

Roche acquires Marcadia Biotech

Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.

Read More

Local economic espionage case full of intrigue

The government's allegations read like a spy novel: Dr. Ke-xue "John" Huang lands a job at Indianapolis-based Dow AgroSciences and over five years works himself into a position of trust, with access to trade secrets and processes the company has invested $300 million to develop.

Read More

Ex-Dow AgroSciences employee accused of stealing trade secrets

The U.S. Department of Justice has charged Ke-xue Huang, a native of China’s Hunan province, of stealing trade secrets of
a Dow AgroSciences insecticide and giving them to the People’s Republic of China. Federal agents arrested the former Dow Agro
scientist July 13 in Westboro, Mass.

Read More

AIT Labs moving headquarters, adding 160 jobs

The Indianapolis-based forensics, clinical and pharmaceutical testing firm, led by CEO Michael Evans, plans to invest $74
million to acquire and equip
an existing 90,000-square-foot building in Woodland Corporate Park near West 79th Street and Interstate 465.

Read More

Medical device startup FlowCo enlists Guidant alums

The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.

Read More

Lilly cancels trials for experimental MS drug

Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.

Read More